Literature DB >> 20192728

Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.

Kenta Nakamura1, Brian S Schwartz, Niklas Lindegårdh, Chris Keh, B Joseph Guglielmo.   

Abstract

The safety of high-dose oseltamivir during treatment of 2009 H1N1 influenza A infection for critically ill patients is unknown. Here we report on a case patient with severe, delayed-onset neuropsychiatric symptoms after administration of high-dose oseltamivir. Clinicians should be vigilant to the possible increased risk of complications associated with high-dose oseltamivir therapy for 2009 H1N1 influenza A infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192728     DOI: 10.1086/651166

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Influenza and the use of oseltamivir in children.

Authors:  Ergin Çiftçi; Adem Karbuz; Tanıl Kendirli
Journal:  Turk Pediatri Ars       Date:  2016-06-01

2.  Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database.

Authors:  Hisashi Urushihara; Yuko Doi; Masaru Arai; Toshiyuki Matsunaga; Yosuke Fujii; Naoko Iino; Takashi Kawamura; Koji Kawakami
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

3.  Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.

Authors:  Yu Jung Cha; Jong Lyul Ghim
Journal:  J Korean Med Sci       Date:  2017-09       Impact factor: 2.153

4.  Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir.

Authors:  Miki Hiasa; Yumiko Isoda; Yasushi Kishimoto; Kenta Saitoh; Yasuaki Kimura; Motomu Kanai; Masakatsu Shibasaki; Dai Hatakeyama; Yutaka Kirino; Takashi Kuzuhara
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

5.  Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.

Authors:  Nayoung Han; Jung Mi Oh; In-Wha Kim
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.